J.P. Morgan Reiterates Overweight Rating, $26 PT on Insulet Corporation on Updated Estimates

In a report published Friday, J.P. Morgan reiterated its Overweight rating and $26.00 price target on Insulet Corporation PODD. J.P. Morgan noted, “Insulet manufactures the OmniPod insulin pump system, which is a wireless, tubing-free alternative to traditional pump therapy primarily targeting Type I diabetics. We view Insulet as uniquely positioned with a differentiated offering in an under-penetrated market. Awareness of the OmniPod system continues to increase, with revenues projected to grow over 20% through 2015. Insulet recently received approval for the company's next-generation Pod, which is 30% smaller and 25% lighter, which should drive continued sales growth along with margin expansion over the next several years.” Insulet Corporation closed on Thursday at $21.61.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsJ.P. Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!